Development of cell-free protein synthesis platforms for discovery and/or production of biologicals[E8]

公告より

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: Biopharmaceutical industries get access to streamlined development and production processes for peptide- or protein-based biologicals. Health systems benefit from the availability of enhanced or decentralised production systems for innovative health technologies that involve peptides or proteins, and which improve health and care. Citizens and patients will benefit from better access, availability and affordability of pharmaceuticals based on biologicals. Scope: Cell-Free Protein Synthesis (CFPS) has been employed in fundamental biological research for decades, however, interest for the approach as a viable means for drug development and production has only emerged in recent years. The advantages that CFPS provides in terms of efficiency, simplicity, flexibility, cost- and time savings outweigh the hurdles that are still to be overcome for CFPS to become a routine manufacturing system for peptide- or protein-based biologicals. Currently, there are several CFPS systems used that are either based on prokaryotic or eukaryotic cell lysates (including mammalian) or fully synthetic systems consi…[E3]

公告の詳細は情報源が公開したとおりに表示しています。当社が抽出する事実と要件は英語で記載しています。

• 対象Universities and research. 掲載文の言葉から SLETOR が分類しました。
• 条件EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• リスクThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• 不明We read the funder's listing, not the full guidance or application forms.

1. 入札受付開始 · 2026年10月29日, 07:41 UTC

   The funder published the call with a future closing date.

   変更：status, notice type, published at (元の記録 Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01))

2. 初回取得 · 2026年10月28日, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   元の記録: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)

このページの情報はすべて資金提供者の掲載情報からのものです。各項目に読み取った記録と項目名を示します。

1. E1

   The funder is European Commission.

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/deadlineDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Maintaining an innovative, sustainable, and competitive EU health industry”. To that end, proposals under this topic should aim to deli…”

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/descriptionByte/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/type/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

5. E5

   This is an EU call for proposals.

   “31094502”

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/startDate/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/status/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

8. E8

   The notice is titled "Development of cell-free protein synthesis platforms for discovery and/or production of biologicals".

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/title/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   出典: Development of cell-free protein synthesis platforms for discovery and/or produ… (ID HORIZON-HLTH-2027-01-IND-01)、 項目 /metadata/budgetOverview/0, 2026年10月29日, 07:41 UTCに読み取り · 情報源 ↗ （新しいタブで開きます）

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. データのライセンス： Creative Commons Attribution 4.0 (European Commission) ↗ （新しいタブで開きます）. 公告に含まれる個人の連絡先は保存も表示もしません。